BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 8411728)

  • 1. [Molecular genetics of neurofibromatosis type 1].
    Suzuki H; Takahashi K; Shibahara S
    Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
    Weiss B; Bollag G; Shannon K
    Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.
    Basu TN; Gutmann DH; Fletcher JA; Glover TW; Collins FS; Downward J
    Nature; 1992 Apr; 356(6371):713-5. PubMed ID: 1570015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21.
    Hattori S; Maekawa M; Nakamura S
    Oncogene; 1992 Mar; 7(3):481-5. PubMed ID: 1549362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
    Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
    Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
    Bollag G; Clapp DW; Shih S; Adler F; Zhang YY; Thompson P; Lange BJ; Freedman MH; McCormick F; Jacks T; Shannon K
    Nat Genet; 1996 Feb; 12(2):144-8. PubMed ID: 8563751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines.
    Andersen LB; Fountain JW; Gutmann DH; Tarlé SA; Glover TW; Dracopoli NC; Housman DE; Collins FS
    Nat Genet; 1993 Feb; 3(2):118-21. PubMed ID: 8499944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hunt for the neurofibromatosis gene.
    Goldberg NS; Collins FS
    Arch Dermatol; 1991 Nov; 127(11):1705-7. PubMed ID: 1952978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of rasGAP and neurofibromatosis gene product activities.
    Bollag G; McCormick F
    Nature; 1991 Jun; 351(6327):576-9. PubMed ID: 1904555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders.
    Side L; Taylor B; Cayouette M; Conner E; Thompson P; Luce M; Shannon K
    N Engl J Med; 1997 Jun; 336(24):1713-20. PubMed ID: 9180088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced neurofibromin content but normal GAP activity in a patient with neurofibromatosis type 1 caused by a five base pair duplication in exon 12b of the NF1 gene.
    Böddrich A; Griesser J; Horn D; Kaufmann D; Krone W; Nürnberg P
    Biochem Biophys Res Commun; 1995 Sep; 214(3):895-904. PubMed ID: 7575561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation.
    Nishi T; Lee PS; Oka K; Levin VA; Tanase S; Morino Y; Saya H
    Oncogene; 1991 Sep; 6(9):1555-9. PubMed ID: 1923522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention.
    Parada LF; Kwon CH; Zhu Y
    Cold Spring Harb Symp Quant Biol; 2005; 70():173-6. PubMed ID: 16869751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations in the neurofibromatosis 1 gene in human tumors.
    Li Y; Bollag G; Clark R; Stevens J; Conroy L; Fults D; Ward K; Friedman E; Samowitz W; Robertson M
    Cell; 1992 Apr; 69(2):275-81. PubMed ID: 1568247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific expression of the neurofibromatosis type 1 gene (NF1) in the hamster Schwann cell.
    Nakamura T; Nemoto T; Arai M; Yamazaki Y; Kasuga T; Gutmann DH; Collins FS; Ishikawa T
    Am J Pathol; 1994 Mar; 144(3):549-55. PubMed ID: 8129040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
    Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
    Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors.
    Guha A; Lau N; Huvar I; Gutmann D; Provias J; Pawson T; Boss G
    Oncogene; 1996 Feb; 12(3):507-13. PubMed ID: 8637706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.